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Hyongbum KimAbstract
Peer reviewers are the unsung heroes of science. We
celebrate reviewers through a series of interviews with
people who have made particularly strong recent
contributions to Genome Biology as reviewers. The first
interview is with Hyongbum (Henry) Kim, an Associate
Professor at Yonsei University College of Medicine in
South Korea.ase and again achieved enrichment using this systemPlease tell us about your research interests
Since 2010, when I become an independent researcher,
the primary focus of our lab has been to develop efficient
and robust methods that enable genome engineering in
various cell types and organisms, including mammalian
cells and mice. The ultimate goal of our research is to con-
tribute to the development of novel therapeutic modalities
for various diseases using genome engineering methods.
Back in 2010, zinc finger nucleases were the only type
of programmable nuclease available for genome editing.Correspondence: hkim1@yuhs.ac
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low, necessitating significant effort and time for making
knockout cell lines. To overcome this problem, Jin-Soo
Kim’s group at Seoul National University and our group
developed and tested a reporter for zinc finger nuclease
activity [1]. Using this reporter we were able to enrich
for cells in which the target gene was disrupted by up to
92-fold. We next improved this reporter [2] and applied
it to gene editing mediated by the CRISPR-Cas9 nucle-
(often more than 10-fold) [3].
Our group also showed the possibility of “safer” genome
editing using cell-penetrating peptides to achieve plasmid-
free delivery of Cas9 protein and guide RNA. This
approach reduces off-target effects and avoids mutagen-
esis caused by insertion of delivery vectors [4]. Based
on these experiences in genome editing, Jin-Soo and I
wrote a review article entitled “A guide to genome en-
gineering with programmable nucleases” [5]. Our group
also showed, using TALENs, that this gene-disruption
approach can convert the blood group of erythroblasts
from RhD positive to RhD negative [6].
Currently, we are trying to improve and/or develop
genome-wide nuclease libraries for disruption of cod-
ing and noncoding elements. Other ongoing projects
in the lab include potential therapeutic applications of
CRISPR-Cas9 to genetic eye and liver diseases. We
are also interested in high-throughput approaches for
evaluating the activity of CRISPR-Cas9 based on target
sequences. We will continue our research to improve or
develop genome editing tools for biomedical research and
biotechnology and apply these advanced genome editing
methods as therapeutic modalities for various diseases.What are your predictions for the field over the
next 5 years?
I expect that genome-editing technology will be continu-
ously improved. The efficiency of genome editing will be
enhanced and the range of tools will be widened. Cur-
rently, CRISPR-Cas9 is the dominant method for genomele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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which could be alternative or complementary to CRISPR-
Cas9.
I expect that issues associated with off-target nuclease
activity may be a less significant problem in the future.
We already have unbiased methods for detecting off-
target effects and more sensitive methods will be avail-
able in the near future. After identifying potential off-
target effects, we will be able to predict their potential
adverse effects. If a nuclease has off-target effects that
could cause significant problems, such as cancer devel-
opment, then we can choose another nuclease. Further-
more, there are already methods available for reducing
off-target effects, such as the use of high fidelity Cas9
nucleases, paired nickases, truncated guide RNAs, or a
combination of FokI nuclease with dead Cas9, as well as
decreasing the duration of nuclease activity (reviewed in
[7]). I would expect that we may not be able to prevent
100 % of the problems induced by off-target effects.
However, there will be many cases for which the benefit
of genome editing will be much greater than the poten-
tial risk of adverse effects caused by off-target activity.
Efficient delivery of genome-editing factors to somatic
cells in vivo may remain challenging; a large amount of
effort will probably be needed to increase efficiency.
Similarly, delivery of RNA interference-inducing factors,
such as small interfering RNA (siRNA) or small hairpin
RNA (shRNA), is one of the biggest road blocks for the
application of this technology. However, transient deliv-
ery of genome-editing factors is sufficient for genome
editing, in contrast to siRNA or shRNA, which often
require continuous delivery. Thus, the burden or diffi-
culty of genome-editing factor delivery to achieve a
therapeutic or biotechnological goal may be lower than
that for RNA interference.What motivates you to provide peer review for
journals?
First, the peer review process gives me a good feeling
that I am serving the scientific community. When I click
the “agree” button to accept the review request, I feel
like that I am donating something to the community.
Second, in some cases, during the review process, I can
get the latest scientific information, which can indirectly
affect my research. Third, the improvement of the
manuscript by my comments gives me positive satisfac-
tion that I have indirectly contributed to the paper.
Given that the number of papers that readers can read is
limited, it is important to publish papers that are suffi-
ciently novel, logical, and complete. My comments often
improve the manuscript significantly and correct errors
in the paper, which will eventually give better informa-
tion to its readers.What changes, if any, would you make to the
current system of peer review?
First, I would like to suggest an establishment of a manu-
script transfer system across different journal groups. This
system could reduce the burden on reviewers and acceler-
ate the publication of the paper. There are good internal
transfer systems within some big journal groups. However,
transfer of manuscripts between different journal groups
is currently difficult.
Second, I would suggest publication of reviewers’ com-
ments even if a paper is rejected from a journal, if the
authors want to share with others. There are some journals
that publish reviewers’ comments when the paper is
accepted. To reduce the probability of unfair review, I
would suggest online publication of the rejected manu-
script together with the comments when authors choose
this option after the paper undergoes peer review. These
online publications may be made available at preprint
servers or at the journal sites themselves if the editors
agree.
I think that these two suggestions may also have some
adverse effects. However, given that such changes would
be expected to make manuscript publication faster and
fairer, they would be cost-effective approaches for facili-
tating the development of science.Have you had any memorably good or bad
experiences of peer review, as an author or as a
reviewer?
I have had one particularly good experience as a peer
reviewer. I was requested to review a paper that was a cre-
ative and novel work in this field. However, the manuscript
had many errors and there were a lot of points that needed
to be addressed before publication. I commented on those
issues in detail. Several months later, a much improved
version of the paper was sent to me and I was happy to see
the improvement. I felt like I was involved in the study.
I had a bad experience regarding peer review as an
author, as most scientists have. I submitted a presubmis-
sion inquiry about my paper to a journal. The editor
sent me positive feedback and I decided to submit my
paper to that journal. During the submission, I found
that I had the option for double-blind review, in which
the authors are anonymous to the reviewers. Because I
thought that double-blind review would lead to fairer
review, I selected that option. Subsequently, my paper
was severely and, in some aspects, unfairly criticized by
the reviewers. My guess is that the reviewers may have
thought that the anonymous authors would not have
sufficient experience to discover something important
and new in the research field. Although it is not clear
whether double-blind review was a part of the reason for
the severe criticisms, I believe that fairer and less biased
Kim Genome Biology  (2016) 17:200 Page 3 of 3reviews will be performed if double-blind reviews are
mandatory rather than optional.
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